Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
Back

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

Completed

Open to: ALL

Age: 35.0 - 80.0

London

Medical Conditions

Parkinson Disease

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified presence or absence of variations in the leucine-rich repeated kinase 2 (LRRK2) gene, but also for patients without any verified PD-related genetic variant.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2019 Aug 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Administered as specified in the treatment arm.

Intervention Arm Group : Part A (SAD): BIIB094 Dose 1;Part A (SAD): BIIB094 Dose 2;Part A (SAD): BIIB094 Dose 3;Part A (SAD): BIIB094 Dose 4;Part A (SAD): BIIB094 Dose 5;Part A (SAD): BIIB094 Dose 6;Part B (MAD): BIIB094 (LRRK2) Dose 2;Part B (MAD): BIIB094 (LRRK2) Dose 3;Part B (MAD): BIIB094 (Non LRRK2) Dose 2;Part B (MAD): BIIB094 (Non LRRK2) Dose 3;Part B (MAD): BIIB094 Dose 1;

Intervention Type : DRUG
Intervention Description : Administered as specified in the treatment arm.

Intervention Arm Group : Part A (SAD): Matching Placebo;Part B (MAD): Matching Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Queen Square (Neurology) CRF Site Institute of Neurology & the National Hospital for Neurology and Neurosurgery UCLH
    London
    WC1N 3BG


The study is sponsored by Biogen and is in collaboration with Ionis Pharmaceuticals, Inc..




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03976349
Last updated 25 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top